2 Gulbenkian Institute for Molecular Medicine, Digital Technologies, Oeiras, Portugal The Journal of Headache and Pain 2026 , 27(S1): P252 Objective To evaluate the safety and side effect profile of anti-CGRP monoclonal antibodies (mAbs) in a real-world cohort of migraine patients, with particular attention to vascular-related events and blood pressure changes
Saroglitazar, a PPAR-/ agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial
LifeMD remains dedicated to elevating access to quality medical care, which starts with offering healthcare that is more patient-centric, affordable and convenient
Helal MM, AbouShawareb H, Abbas OH, et al
Aetna's pharmacy change notice for July 1, 2025 lists Zepbound under "Endocrine and Metabolic, Antiobesity" as a removed drug, with orlistat, Qsymia, Saxenda, and Wegovy named as the formulary alternatives